Active — Not RecruitingPhase 1/2

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

United States, Argentina, Austria438 participantsStarted 2019-05-20

Plain-language summary

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria * History of Non-Hodgkin's Lymphoma (NHL) with relapsed or refractory disease. * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2. Exclusion Criteria * Life expectancy ≤ 2 months. * Received prior systemic anti-cancer treatment (approved or investigational) ≤ 5 half-lives or 4 weeks prior to starting CC-99282, whichever is shorter. * Is on chronic systemic immunosuppressive therapy or corticosteroids or has clinically significant graft-versus-host disease (GVHD). * Impaired cardiac function or clinically significant cardiac disease. * Other protocol-defined inclusion/exclusion criteria apply.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Incidence of Adverse Events (AEs)

Timeframe: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)

Number of participants with laboratory abnormalities

Timeframe: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)

Number of participants with vital sign abnormalities

Timeframe: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)

Number of participants with electrocardiogram (ECG) abnormalities

Timeframe: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)

Number of participants with Eastern Cooperative Oncology Group (ECOG) performance status abnormalities

Timeframe: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)

Number of participants with left ventricular ejection fraction (LVEF) assessment abnormalities

Timeframe: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)

Trial details

NCT IDNCT03930953

SponsorCelgene

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-04-07

View on ClinicalTrials.gov More Lymphoma, Non-Hodgkin trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Incidence of Adverse Events (AEs)

Timeframe: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)

Number of participants with laboratory abnormalities

Timeframe: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)

Number of participants with vital sign abnormalities

Timeframe: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)

Number of participants with electrocardiogram (ECG) abnormalities

Timeframe: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)

Number of participants with Eastern Cooperative Oncology Group (ECOG) performance status abnormalities

Timeframe: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)

Number of participants with left ventricular ejection fraction (LVEF) assessment abnormalities

Timeframe: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)